AgeX Therapeutics (NYSEAM:AGE) - Aandelenkoers, Nieuws & Analyse

AGE Overzicht aandelen

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. Meer informatie

AGE fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Heeft een omzet van minder dan 1 miljoen USD ( $142K )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

De winst is de afgelopen 5 jaar met 2.6% per jaar gedaald

+ 2 meer risico's

AgeX Therapeutics, Inc. Concurrenten

Gain Therapeutics

NasdaqGM:GANX

US$45.9m

Shattuck Labs

NasdaqGS:STTK

US$51.6m

Affimed

NasdaqGM:AFMD

US$47.0m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor AgeX Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$11.10
52 Week Hoogtepunt	US$35.17
52 Week Laag	US$10.90
Bèta	1.19
11 maand verandering	-14.70%
3 maanden verandering	-23.49%
1 Jaar Verandering	-48.68%
33 jaar verandering	-80.64%
5 jaar verandering	-92.39%
Verandering sinds IPO	-88.35%

Recent nieuws en updates

Recent updates

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

Feb 09

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Nov 20

Rendement voor aandeelhouders

	AGE	US Biotechs	US Markt
7D	-23.6%	4.3%	1.6%
1Y	-48.7%	18.8%	32.3%

Rendement versus industrie: AGE presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18.8 % opleverde.

Rendement versus markt: AGE presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.3 % opleverde.

Prijsvolatiliteit

Is AGE's price volatile compared to industry and market?
AGE volatility
AGE Average Weekly Movement	18.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van AGE is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 18% ) van AGE is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	6	Joanne Hackett	www.agexinc.com

AgeX Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van AgeX Therapeutics zich tot de beurswaarde?
AGE fundamentele statistieken
Marktkapitalisatie	US$31.51m
Inkomsten(TTM)	-US$14.80m
Inkomsten(TTM)	US$142.00k

195.5x

P/S-verhouding

-1.9x

Koers/Winstverhouding

Is AGE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AGE resultatenrekening (TTM)
Inkomsten	US$142.00k
Kosten van inkomsten	US$40.00k
Brutowinst	US$102.00k
Overige uitgaven	US$14.91m
Inkomsten	-US$14.80m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-5.92
Brutomarge	71.83%
Nettowinstmarge	-10,424.65%
Schuld/Eigen Vermogen Verhouding	81.5%

Hoe presteerde AGE op de lange termijn?

Bekijk historische prestaties en vergelijking

AGE Overzicht aandelen

Risicoanalyse

AgeX Therapeutics, Inc. Concurrenten

NasdaqGM:GANX

US$45.9m

NasdaqGS:STTK

US$51.6m

NasdaqGM:AFMD

US$47.0m

NasdaqGS:FIXX

US$54.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. (NYSEAM:AGE) from a group of shareholders in a reverse merger transaction.

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Recent updates

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. (NYSEAM:AGE) from a group of shareholders in a reverse merger transaction.

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Agex Therapeutics Provides Non-Compliance Update Related to Stock Holders Equity

AgeX Therapeutics Announces Appeal of NYSE American Determination

NYSE American to Suspend Trading Immediately in Agex Therapeutics and Commence Delisting Proceedings

Third quarter 2022 earnings released: US$0.064 loss per share (vs US$0.052 loss in 3Q 2021)

AgeX Therapeutics, Inc., Annual General Meeting, Dec 07, 2022

Second quarter 2022 earnings released: US$0.069 loss per share (vs US$0.065 loss in 2Q 2021)

AgeX Therapeutics, Inc. Announces Board Changes

First quarter 2022 earnings released: US$0.071 loss per share (vs US$0.053 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.29 loss in FY 2020)

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. announced that it expects to receive $13.16 million in funding from Juvenescence Ltd.

Less than half of directors are independent

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.067 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.065 loss per share (vs US$0.071 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.053 loss per share (vs US$0.085 loss in 1Q 2020)

Full year 2020 earnings released: US$0.29 loss per share (vs US$0.33 loss in FY 2019)

Agex Therapeutics to Collaborate with the Ohio State University to Generate Proof-Of-Concept Animal Data for Agex’s Brown Adipose Tissue (Bat) Cell Therapy Candidate for Diabetes and Obesity

Atlas Capital Group Ltd. entered into an agreement to acquire LifeMap Sciences Ltd from AgeX Therapeutics, Inc. (AMEX:AGE).

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

New 90-day high: US$2.06

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

New 90-day high: US$1.94

AgeX Therapeutics, Inc., Annual General Meeting, Dec 28, 2020

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Third quarter 2020 earnings released: US$0.067 loss per share

New 90-day high: US$2.48

First half earnings released

New 90-day high - US$1.52

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 3000 Growth Index

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell Microcap Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

AgeX Therapeutics, Inc. Samenvatting

195.5x

-1.9x

Inkomsten en omzet